1. Home
  2. AGBK vs KALV Comparison

AGBK vs KALV Comparison

Compare AGBK & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AGBK

AGI Inc Class A Common Shares

N/A

Current Price

$6.63

Market Cap

1.1B

Sector

Finance

ML Signal

N/A

Logo KalVista Pharmaceuticals Inc.

KALV

KalVista Pharmaceuticals Inc.

HOLD

Current Price

$20.09

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGBK
KALV
Founded
1999
N/A
Country
Brazil
United States
Employees
N/A
N/A
Industry
Commercial Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.0B
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
AGBK
KALV
Price
$6.63
$20.09
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
5
Target Price
$17.20
$32.60
AVG Volume (30 Days)
621.7K
1.2M
Earning Date
03-23-2026
05-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$50,000,000.00
Revenue This Year
N/A
$187.19
Revenue Next Year
$235.22
$54.93
P/E Ratio
$46.19
N/A
Revenue Growth
N/A
495.66
52 Week Low
$6.76
$9.83
52 Week High
$12.21
$21.31

Technical Indicators

Market Signals
Indicator
AGBK
KALV
Relative Strength Index (RSI) 23.66 66.43
Support Level N/A $14.66
Resistance Level $7.56 N/A
Average True Range (ATR) 0.61 1.35
MACD -0.11 0.27
Stochastic Oscillator 5.62 82.78

Price Performance

Historical Comparison
AGBK
KALV

About AGBK AGI Inc Class A Common Shares

AGI Inc is a technology-powered provider of specialized financial services in Brazil. It empowers clients to access their social security benefits, severance fund benefits, and public or private sector payrolls through secured lending solutions and complementary banking, credit and insurance products tailored as per client needs. The company has one operating segment related to the banking business. The Bank provides a standardized set of financial products and services exclusively to individuals, mainly focused on credit, including digital accounts, cards, payroll and personal loans, and insurance offered through partners.

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

Share on Social Networks: